Literature DB >> 21827811

An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.

Valerian B Pinto1, Elizabeth E Moran, Francisco Cruz, Xin-Ming Wang, Arthur Fridman, Wendell D Zollinger, Craig T Przysiecki, Robert Burden.   

Abstract

A trivalent native outer membrane vesicle vaccine that has potential to provide broad based protection against Neisseria meningitidis serogroup B strains has been developed. Preliminary immunogenicity studies in mice showed that the vaccine was capable of inducing an effective broad based bactericidal antibody response against N. meningitidis serogroup B strains. These findings in mice have been repeated with a cGMP trivalent NOMV vaccine and extended to show that the bactericidal antibody response induced by the vaccine in mice is effective against strains belonging to serogroups C, Y, W135, X, and NadA-expressing serogroup A strains. Taken together these results suggest that this experimental vaccine may provide protection against both serogroup B and non-serogroup B N. meningitidis strains. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827811     DOI: 10.1016/j.vaccine.2011.07.124

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Authors:  Rolando Pajon; Carolyn M Buckwalter; Kay O Johswich; Scott D Gray-Owen; Dan M Granoff
Journal:  Vaccine       Date:  2015-02-04       Impact factor: 3.641

2.  Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine.

Authors:  Lawrence W Dick; John T Mehl; John W Loughney; Anna Mach; Richard R Rustandi; Sha Ha; Lan Zhang; Craig T Przysiecki; Lance Dieter; Van M Hoang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.

Authors:  Jay Lucidarme; Stefanie Gilchrist; Lynne S Newbold; Stephen J Gray; Edward B Kaczmarski; Lynne Richardson; Julia S Bennett; Martin C J Maiden; Jamie Findlow; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

Review 4.  The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.

Authors:  Davide Serruto; Matthew J Bottomley; Sanjay Ram; Marzia M Giuliani; Rino Rappuoli
Journal:  Vaccine       Date:  2012-05-30       Impact factor: 3.641

5.  Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.

Authors:  Elizabeth E Moran; Robert Burden; Joseph E Labrie; Zhiyun Wen; Xin-Min Wang; Wendell D Zollinger; Lan Zhang; Valerian B Pinto
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

6.  Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.

Authors:  Bas van de Waterbeemd; Gijsbert Zomer; Patricia Kaaijk; Nicole Ruiterkamp; René H Wijffels; Germie P J M van den Dobbelsteen; Leo A van der Pol
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 7.  The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

Authors:  Michael W Shea
Journal:  Ann Med Surg (Lond)       Date:  2013-11-04

8.  Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Authors:  Abel E Vasquez; Ricardo A Manzo; Daniel A Soto; Magaly J Barrientos; Aurora E Maldonado; Macarena Mosqueira; Anastasia Avila; Jorge Touma; Elsa Bruce; Paul R Harris; Alejandro Venegas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Rolando Pajon; Emily M Braga; Sanjay Ram; Dan M Granoff
Journal:  PLoS Pathog       Date:  2012-05-10       Impact factor: 6.823

10.  The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.

Authors:  Valerian B Pinto; Robert Burden; Allyn Wagner; Elizabeth E Moran; Che-Hung Lee
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.